Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.

The two-dose Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), has been developed by the Janssen Pharmaceutical Companies of Johnson & Johnson for the prevention of Ebola Virus Disease caused by the Zaire Ebola virus species. The vaccine regimen leveraged Janssen’s AdVac® vaccine technology, plus Bavarian Nordic’s established MVA-BN® technology. It is specifically designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above. As such, it can be used to support preventive vaccination in countries most at risk of outbreaks.

The University of Oxford played an important role in supporting the development of this vaccine. In response to the West Africa Ebola crisis, we collaborated in a unique, multi-partner global effort to accelerate the vaccine through multiple clinical trials across three continents.

The full story is available on the University of Oxford website